6-K
Radiopharm Theranostics Ltd (RADX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of December 2024
Commission File Number: 001-41621
RADIOPHARM THERANOSTICS LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South,Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
RADIOPHARM THERANOSTICS LIMITED
EXPLANATORY NOTE
Radiopharm Theranostics Limited (the “Company”) published four announcements (the “Public Notices”) to the Australian Securities Exchange on December 18, 2024 titled:
| - | “Application for<br> quotation of securities – RAD” |
|---|---|
| - | “Notification regarding<br> unquoted securities – RAD” |
| - | “Change of Director’s<br> Interest Notices x7” |
| - | “Notification of<br> cessation of securities – RAD” |
A copy of the Public Notices are attached as an exhibit to this report on Form 6-K.
This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
1
EXHIBITS
| Exhibit <br><br>Number | Description |
|---|---|
| 99.1 | Application for quotation of securities – RAD |
| 99.2 | Notification regarding unquoted securities – RAD |
| 99.3 | Change of Director’s Interest Notices x7 |
| 99.4 | Notification of cessation of securities – RAD |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| RADIOPHARM THERANOSTICS LIMITED | ||
|---|---|---|
| Date: December 18 2024 | By: | /s/ Phillip Hains |
| Phillip Hains | ||
| Company Secretary |
3
Exhibit 99.1
| Appendix 2A - Application for quotation of securities |
|---|
Announcement Summary
Entity name
RADIOPHARM THERANOSTICS LIMITED
Announcement Type
New announcement
Date of this announcement
Wednesday December 18, 2024
The +securities to be quoted are:
Other
Please refer to the response to Q2.3d for further informationabout the type of securities to be quoted and the circumstances of the issue.
| Forfeiture shares per employee contract |
|---|
Total number of +securities to be quoted
| Number of +securities to | ||||
|---|---|---|---|---|
| ASX +security code | Security description | be quoted | Issue date | |
| RAD | ORDINARY FULLY PAID | 7,091,615 | 16/12/2024 |
Refer to next page for full details of the announcement
| Appendix 2A - Application for quotation of securities | 1 / 6 |
| --- | --- | | Appendix 2A - Application for quotation of securities | | --- | | Part 1 - Entity and announcement details | | --- |
1.1 Name of entity
RADIOPHARM THERANOSTICS LIMITED
We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.
| 1.2 Registered number type | Registration number |
|---|---|
| ACN | 647877889 |
| 1.3 ASX issuer code | |
| --- | |
| RAD |
1.4 The announcement is
New announcement
1.5 Date of this announcement
18/12/2024
| Appendix 2A - Application for quotation of securities | 2 / 6 |
| --- | --- | | Appendix 2A - Application for quotation of securities | | --- | | Part 2 - Type of Issue | | --- |
2.1 The +securities to be quoted are:
Other
Please refer to the response to Q2.3d for further informationabout the type of securities to be quoted and the circumstances of the issue.
2.2 The +class of +securities to be quoted is:
Additional +securities in a class that is already quoted on ASX (“existing class”)
2.3c Have these +securities been offered under a +disclosuredocument or +PDS?
No
2.3d Please provide any further information needed tounderstand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securitieshas not been previously announced to the market in an Appendix 3B
| Forfeiture shares per employee contract |
|---|
2.4 Any on-sale of the +securities to be quoted within12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Actby virtue of:
The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)
| Appendix 2A - Application for quotation of securities | 3 / 6 |
| --- | --- | | Appendix 2A - Application for quotation of securities | | --- |
Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B
Additional +securities to be quoted in an existing class
ASX +security code and description
RAD : ORDINARY FULLY PAID
Issue date
16/12/2024
Will the +securities to be quoted rank equally in allrespects from their issue date with the existing issued +securities in that class?
Yes
Issue details
Number of +securities to be quoted
7,091,615
Are the +securities being issued for a cash consideration?
No
Pleasedescribe the consideration being provided for the +securities
| Forfeiture shares per employee contract. |
|---|
Please provide an estimate (in AUD) of the value ofthe consideration being provided per +security for the +securities to be quoted
0.031000
Any other information the entity wishes to provide aboutthe +securities to be quoted
The purpose(s) for which the entity is issuing the securities
Other
Please provide additional details
| Forfeiture shares per employee contract. |
|---|
| Appendix 2A - Application for quotation of securities | 4 / 6 |
| --- | --- | | Appendix 2A - Application for quotation of securities | | --- | | Part 4 - Issued capital following quotation | | --- |
Following the quotation of the +securities the subjectof this application, the issued capital of the entity will comprise:
The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity’s current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.
4.1 Quoted +securities (total number of each +classof +securities quoted on ASX following the +quotation of the +securities subject of this application)
| Total number of +securities | ||
|---|---|---|
| ASX +security code and description | on issue | |
| RADO : OPTION EXPIRING 30-NOV-2026 | 79,352,040 | |
| RAD : ORDINARY FULLY PAID | 2,180,052,371 | |
| RADOA : OPTION EXPIRING 24-AUG-2026 | 818,890,534 |
4.2 Unquoted +securities (total number of each +class of+securities issued but not quoted on ASX)
| ASX +security code and description | |
| RADAK : OPTION EXPIRING 01-JUN-2027 EX 0.60 | 2,500,000 |
| RADAE : OPTION EXPIRING 25-NOV-2025 RESTRICTED | 5,700,006 |
| RADAN : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES | 72,262,387 |
| RADAJ : OPTION EXPIRING 01-JUL-2027 EX 0.17 | 13,137,976 |
| RADAF : OPTION EXPIRING 25-NOV-2026 RESTRICTED | 8,666,678 |
| RADAG : OPTION EXPIRING 25-NOV-2026 EX 0.60 | 5,066,672 |
| RADAH : OPTION EXPIRING 22-DEC-2025 EX 0.60 | 400,000 |
| RADAI : OPTION EXPIRING 27-MAY-2027 EX 0.60 | 740,000 |
| RADAP : OPTION EXPIRING 24-APR-2028 EX 0.09 | 8,955,224 |
| RADAAA : OPTION EXPIRING 24-FEB-2025 EX 0.05 | 149,925,040 |
All values are in US Dollars.
| Appendix 2A - Application for quotation of securities | 5 / 6 |
| --- | --- | | Appendix 2A - Application for quotation of securities | | --- | | Part 5 - Other Listing Rule requirements | | --- |
5.1 Are the +securities being issued under an exceptionin Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?
No
5.2 Has the entity obtained, or is it obtaining, +securityholder approval for the issue under listing rule 7.1?
No
5.2b Are any of the +securities being issued without+security holder approval using the entity’s 15% placement capacity under listing rule 7.1?
Yes
5.2b.1 How many +securities are being issued without+security holder approval using the entity’s 15% placement capacity under listing rule 7.1?
| 7,091,615 |
|---|
5.2c Are any of the +securities being issued without+security holder approval using the entity’s additional 10% placement capacity under listing rule 7.1A (if applicable)?
No
| Appendix 2A - Application for quotation of securities | 6 / 6 |
| --- | --- |
Exhibit 99.2
| Appendix 3G -<br>Notification of issue, conversion or payment up of unquoted equity securities |
|---|
| Announcement Summary |
| --- |
Entity name
RADIOPHARM THERANOSTICS LIMITED
Date of this announcement
Wednesday December 18, 2024
The +securities the subject of this notification are:
+Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends
Total number of +securities to be issued/transferred
| ASX +security code | Security description | Total number of +securities to be issued/transferred | Issue date | |
|---|---|---|---|---|
| RADAN | OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES | 140,572,155 | 16/12/2024 |
Refer to next page for full details of the announcement
| Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | 1 / 7 |
|---|---|
| Appendix 3G -<br>Notification of issue, conversion or payment up of unquoted equity securities | |
| --- | |
| Part 1 - Entity and announcement details | |
| --- |
1.1 Name of entity
RADIOPHARM THERANOSTICS LIMITED
We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.
| 1.2 Registered number type | Registration number |
|---|---|
| ACN | 647877889 |
| 1.3 | ASX issuer code |
| --- | --- |
RAD
1.4 The announcement is
New announcement
1.5 Date of this announcement
18/12/2024
| Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | 2 / 7 |
|---|---|
| Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | |
| --- | |
| Part 2 - Issue details | |
| --- |
2.1 The +securities the subject of this notification are:
+Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends
2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:
has an existing ASX security code (“existing class”)
| Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | 3 / 7 |
|---|---|
| Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | |
| --- |
Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B
Additional +securities in an existing class issued under an +employee incentive scheme
ASX +security code and description
RADAN : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES
Date the +securities the subject of this notification were issued
16/12/2024
Will these +securities rank equally in all respectsfrom their issue date with the existing issued +securities in that class
Yes
Were any of the +securities issued to +key management personnel (KMP) or an +associate?
Yes
Provide details of the KMP or +associates being issued +securities.
| Name of KMP | Name of registered holder | Number of +securities | |
|---|---|---|---|
| Riccardo Canevari | Riccardo Canevari | 55,250,286 | |
| Ian Turner | Ian Turner | 12,040,404 | |
| Paul Hopper | Paul Hopper | 8,000,000 | |
| Noel Donnelly | Noel Donnelly | 8,000,000 | |
| Phillip Allen Hains | Phillip Allen Hains | 8,000,000 | |
| Hester Larkin | Hester Larkin | 8,000,000 | |
| Leila Alland | Leila Alland | 8,000,000 |
Please provide a URL link for a document lodged with ASX detailing the terms of the +employeeincentive scheme or a summary of the terms
| Refer to page 49 of the 2024 Notice of Annual General Meeting for the Material terms of the Omnibus Incentive Plan: |
|---|
| https://announcements.asx.com.au/asxpdf/20241025/pdf/069khmnljqvkz4.pdf |
Any other information the entity wishes to provide about the +securities the subject of this notification
| n/a | |
|---|---|
| Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | 4 / 7 |
| --- | --- |
| Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | |
| --- |
Issue details
Number of +securities
140,572,155
| Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | 5 / 7 |
|---|---|
| Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | |
| --- | |
| Part 4 - +Securities on issue | |
| --- |
Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:
The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity’s current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.
4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)
| ASX +security code and description | Total <br> number of <br>+securities on issue | |
|---|---|---|
| RADO : OPTION EXPIRING 30-NOV-2026 | 79,352,040 | |
| RAD : ORDINARY FULLY PAID | 2,172,960,756 | |
| RADOA : OPTION EXPIRING 24-AUG-2026 | 818,890,534 |
4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)
| ASX +security code and description | |
|---|---|
| RADAK : OPTION EXPIRING 01-JUN-2027 EX 0.60 | 2,500,000 |
| RADAE : OPTION EXPIRING 25-NOV-2025 RESTRICTED | 5,700,006 |
| RADAN : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES | 212,834,542 |
| RADAJ : OPTION EXPIRING 01-JUL-2027 EX 0.17 | 13,137,976 |
| RADAF : OPTION EXPIRING 25-NOV-2026 RESTRICTED | 8,666,678 |
| RADAG : OPTION EXPIRING 25-NOV-2026 EX 0.60 | 5,066,672 |
| RADAH : OPTION EXPIRING 22-DEC-2025 EX 0.60 | 400,000 |
| RADAI : OPTION EXPIRING 27-MAY-2027 EX 0.60 | 740,000 |
| RADAP : OPTION EXPIRING 24-APR-2028 EX 0.09 | 8,955,224 |
| RADAAA : OPTION EXPIRING 24-FEB-2025 EX 0.05 | 149,925,040 |
All values are in US Dollars.
| Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | 6 / 7 |
|---|---|
| Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | |
| --- | |
| Part 5 - Other Listing Rule requirements | |
| --- |
5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?
Yes
5.1a Select the number of the applicable exception in Listing Rule 7.2
13
| Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | 7 / 7 |
|---|
Exhibit 99.3
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced30/9/2001. Amended 01/01/11
| Nameof Entity: | Radiopharm<br>Theranostics Limited (ASX: RAD) |
|---|---|
| ABN: | 57<br>647 877 889 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of<br>Director: | Hester Larkin |
|---|---|
| Date of Last Notice: | 18 September 2024 |
Part 1 - Changeof director’s relevant interests in securities
In the case of a trust, thisincludes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or Indirect Interest | Direct | ||
|---|---|---|---|
| Nature of indirect interest (including registered holder) <br><br>Note: Provide details of the circumstances giving rise to the relevant interest. | |||
| Date of change | 16 December 2024 | ||
| No. of securities held prior to change | Shares | Options | |
| --- | --- | --- | --- |
| Direct | 550,000 | 2,175,002 | |
| Indirect | 94,247 | - | |
| Total | 644,247 | 2,175,002 | |
| Class | Unlisted Options | ||
| --- | --- | ||
| Number acquired | Shares | Options | |
| --- | --- | --- | --- |
| Direct | - | 8,000,000 | |
| Indirect | - | - | |
| **** | Total | - | 8,000,000 |
| + See chapter 19 for defined terms. | |||
| --- | --- | ||
| 01/01/2011 | Appendix 3Y Page 1 |
Appendix 3Y
Change of Director’s Interest Notice
| Number disposed | Shares | Options | |
|---|---|---|---|
| Direct | - | - | |
| Indirect | - | - | |
| Total | - | - | |
| Value/Consideration<br><br> <br>Note:<br><br> <br>If consideration<br> is non-cash, provide details and estimated valuation | Non-cash options issued, per resolution 12 approved by shareholders<br>at the Annual General Meeting held on 25 November 2024 | ||
| --- | --- | ||
| No. of securities held after change | Shares | Options | |
| --- | --- | --- | --- |
| Direct | 550,000 | 10,175,002 | |
| Indirect | 94,247 | - | |
| **** | Total | 644,247 | 10,175,002 |
| Nature of change<br><br> <br>Example:<br><br> <br>on-market trade,<br> off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Per resolution 12 approved by shareholders at the Annual General Meeting<br>held on 25 November 2024 | ||
| --- | --- |
Part 2 –Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A |
|---|---|
| Nature of interest | N/A |
| Name of registered holder<br><br> <br>(if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change<br><br> <br>Note: Details<br> are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration<br><br> <br>Note: If consideration is non-cash, provide details<br> and an estimated valuation | N/A |
| Interest after change | N/A |
| + See chapter 19 for defined terms. | |
| --- | --- |
| Appendix 3Y Page 2 | 01/01/2011 |
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – Closed period
| Werethe interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
|---|---|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
| + See chapter 19 for defined terms. | |
|---|---|
| 01/01/2011 | Appendix 3Y Page 3 |
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced30/9/2001. Amended 01/01/11
| Nameof Entity: | Radiopharm<br>Theranostics Limited (ASX: RAD) |
|---|---|
| ABN: | 57<br>647 877 889 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of<br>Director: | Ian Turner |
|---|---|
| Date of Last Notice: | 23 October 2024 |
Part 1 - Changeof director’s relevant interests in securities
In the case of a trust, thisincludes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or Indirect Interest | Direct | ||
|---|---|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | |||
| Date of change | 16 December 2024 | ||
| No. of securities held prior to change | Shares | Options | |
| --- | --- | --- | --- |
| Direct | 2,530,595 | 6,127,524 | |
| Indirect | 2,424,697 | 820,422 | |
| Total | 4,955,292 | 6,947,946 | |
| Class | Unlisted Options | ||
| --- | --- | ||
| Number acquired | Shares | Options | |
| --- | --- | --- | --- |
| Direct | - | A) 4,040,404<br><br> <br>B) 8,000,000 | |
| Indirect | - | - | |
| **** | Total | - | 12,040,404 |
| + See chapter 19 for defined terms. | |||
| --- | --- | ||
| 01/01/2011 | Appendix 3Y Page 1 |
Appendix 3Y
Change of Director’s Interest Notice
| Number disposed | Shares | Options | |
|---|---|---|---|
| Direct | - | - | |
| Indirect | - | - | |
| Total | - | - | |
| Value/Consideration<br><br> <br>Note:<br><br> <br>If consideration<br> is non-cash, provide details and estimated valuation | A) Non-cash options issued, per resolution 8 approved by shareholders at the Annual General Meeting held on 25 November 2024<br><br> <br><br><br> <br>B) Non-cash options issued, per resolution 9 approved by shareholders at the Annual General Meeting held on 25 November 2024 | ||
| --- | --- | ||
| No. of securities held after change | Shares | Options | |
| --- | --- | --- | --- |
| Direct | 2,530,595 | 18,167,928 | |
| Indirect | 2,424,697 | 820,422 | |
| **** | Total | 4,955,292 | 18,988,350 |
| Nature of change<br><br> <br>Example:<br><br> <br>on-market trade,<br> off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Per resolutions 8 & 9 approved by shareholders at the Annual General<br>Meeting held on 25 November 2024 | ||
| --- | --- |
Part 2 –Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A |
|---|---|
| Nature of interest | N/A |
| Name of registered holder<br><br> <br>(if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change<br><br> <br>Note: Details<br> are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration<br><br> <br>Note: If consideration is non-cash, provide details<br> and an estimated valuation | N/A |
| Interest after change | N/A |
| + See chapter 19 for defined terms. | |
| --- | --- |
| Appendix 3Y Page 2 | 01/01/2011 |
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – Closed period
| Werethe interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
|---|---|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
| + See chapter 19 for defined terms. | |
|---|---|
| 01/01/2011 | Appendix 3Y Page 3 |
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced30/9/2001. Amended 01/01/11
| Nameof Entity: | Radiopharm<br>Theranostics Limited (ASX: RAD) |
|---|---|
| ABN: | 57<br>647 877 889 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of<br>Director: | Leila Alland |
|---|---|
| Date of Last Notice: | 18 September 2024 |
Part 1 - Changeof director’s relevant interests in securities
In the case of a trust, thisincludes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or Indirect Interest | Direct | ||
|---|---|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | |||
| Date of change | 16 December 2024 | ||
| No. of securities held prior to change | Shares | Options | |
| --- | --- | --- | --- |
| Direct | 1,071,740 | 2,400,002 | |
| Indirect | - | - | |
| Total | 1,071,740 | 2,400,002 | |
| Class | Unlisted Options | ||
| --- | --- | ||
| Number acquired | Shares | Options | |
| --- | --- | --- | --- |
| Direct | - | 8,000,000 | |
| Indirect | - | - | |
| **** | Total | - | 8,000,000 |
| + See chapter 19 for defined terms. | |||
| --- | --- | ||
| 01/01/2011 | Appendix 3Y Page 1 |
Appendix 3Y
Change of Director’s Interest Notice
| Number disposed | Shares | Options | |
|---|---|---|---|
| Direct | - | - | |
| Indirect | - | - | |
| Total | - | - | |
| Value/Consideration<br><br> <br>Note:<br><br> <br>If consideration<br> is non-cash, provide details and estimated valuation | Non-cash options<br>issued, per resolution 13 approved by shareholders at the Annual General Meeting held on 25 November 2024 | ||
| --- | --- | ||
| No. of securities held after change | Shares | Options | |
| --- | --- | --- | --- |
| Direct | 1,071,740 | 10,400,002 | |
| Indirect | - | - | |
| **** | Total | 1,071,740 | 10,400,002 |
| Nature of change<br><br> <br>Example:<br><br> <br>on-market trade,<br> off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Per resolution 13 approved by shareholders at the Annual General Meeting<br>held on 25 November 2024 | ||
| --- | --- |
Part 2 –Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A |
|---|---|
| Nature of interest | N/A |
| Name of registered holder<br><br> <br>(if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change<br><br> <br>Note: Details<br> are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration<br><br> <br>Note: If consideration is non-cash, provide details<br> and an estimated valuation | N/A |
| Interest after change | N/A |
| + See chapter 19 for defined terms. | |
| --- | --- |
| Appendix 3Y Page 2 | 01/01/2011 |
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – Closed period
| Werethe interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
|---|---|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
| + See chapter 19 for defined terms. | |
|---|---|
| 01/01/2011 | Appendix 3Y Page 3 |
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced30/9/2001. Amended 01/01/11
| Nameof Entity: | Radiopharm<br>Theranostics Limited (ASX: RAD) |
|---|---|
| ABN: | 57<br>647 877 889 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of<br>Director: | Noel Donnelly |
|---|---|
| Date of Last Notice: | 3 October 2024 |
Part 1 - Changeof director’s relevant interests in securities
In thecase of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or Indirect Interest | Direct | ||
|---|---|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | |||
| Date of change | 16 December 2024 | ||
| No. of securities held prior to change | Shares | Options | |
| --- | --- | --- | --- |
| Direct | - | - | |
| Indirect | - | - | |
| Total | - | - | |
| Class | Unlisted Options | ||
| --- | --- | ||
| Number acquired | Shares | Options | |
| --- | --- | --- | --- |
| Direct | - | 8,000,000 | |
| Indirect | - | - | |
| **** | Total | - | 8,000,000 |
| + See chapter 19 for defined terms. | |||
| --- | --- | ||
| 01/01/2011 | Appendix 3Y Page 1 |
Appendix 3Y
Change of Director’s Interest Notice
| Number disposed | Shares | Options | |
|---|---|---|---|
| Direct | - | - | |
| Indirect | - | - | |
| Total | - | - | |
| Value/Consideration<br><br> <br>Note:<br><br> <br>If consideration<br> is non-cash, provide details and estimated valuation | Non-cash options<br>issued, per resolution 10 approved by shareholders at the Annual General Meeting held on 25 November 2024 | ||
| --- | --- | ||
| No. of securities held after change | Shares | Options | |
| --- | --- | --- | --- |
| Direct | - | 8,000,000 | |
| Indirect | - | - | |
| **** | Total | - | 8,000,000 |
| Nature of change<br><br> <br>Example:<br><br> <br>on-market trade,<br> off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Per resolution 10 approved by shareholders at the Annual General Meeting<br>held on 25 November 2024 | ||
| --- | --- |
Part 2 –Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A |
|---|---|
| Nature of interest | N/A |
| Name of registered holder<br><br> <br>(if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change<br><br> <br>Note: Details<br> are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration<br><br> <br>Note: If consideration is non-cash, provide details<br> and an estimated valuation | N/A |
| Interest after change | N/A |
| + See chapter 19 for defined terms. | |
| --- | --- |
| Appendix 3Y Page 2 | 01/01/2011 |
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – Closed period
| Werethe interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
|---|---|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
| + See chapter 19 for defined terms. | |
|---|---|
| 01/01/2011 | Appendix 3Y Page 3 |
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced30/9/2001. Amended 01/01/11
| Nameof Entity: | Radiopharm<br>Theranostics Limited (ASX: RAD) |
|---|---|
| ABN: | 57<br>647 877 889 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of<br>Director: | Phillip Hains |
|---|---|
| Date of Last Notice: | 18 September 2024 |
Part 1 - Changeof director’s relevant interests in securities
In the case of a trust, thisincludes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or Indirect Interest | Direct | ||
|---|---|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | |||
| Date of change | 16 December 2024 | ||
| No. of securities held prior to change | Shares | Options | |
| --- | --- | --- | --- |
| Direct | - | 1,900,002 | |
| Indirect | 15,956,632 | 6,933,560 | |
| Total | 15,956,632 | 8,833,562 | |
| Class | Unlisted Options | ||
| --- | --- | ||
| Number acquired | Shares | Options | |
| --- | --- | --- | --- |
| Direct | - | 8,000,000 | |
| Indirect | - | - | |
| **** | Total | - | 8,000,000 |
| + See chapter 19 for defined terms. | |||
| --- | --- | ||
| 01/01/2011 | Appendix 3Y Page 1 |
Appendix 3Y
Change of Director’s Interest Notice
| Number disposed | Shares | Options | |
|---|---|---|---|
| Direct | - | - | |
| Indirect | - | - | |
| Total | - | - | |
| Value/Consideration<br><br> <br>Note:<br><br> <br>If consideration<br> is non-cash, provide details and estimated valuation | Non-cash options issued, per resolution 11 approved by shareholders<br>at the Annual General Meeting held on 25 November 2024 | ||
| --- | --- | ||
| No. of securities held after change | Shares | Options | |
| --- | --- | --- | --- |
| Direct | - | 9,900,002 | |
| Indirect | 15,956,632 | 6,933,560 | |
| **** | Total | 15,956,632 | 16,833,562 |
| Nature of change<br><br> <br>Example:<br><br> <br>on-market trade,<br> off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Per resolution 11 approved by shareholders at the Annual General Meeting<br>held on 25 November 2024 | ||
| --- | --- |
Part 2 –Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A |
|---|---|
| Nature of interest | N/A |
| Name of registered holder<br><br> <br>(if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change<br><br> <br>Note: Details<br> are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration<br><br> <br>Note: If consideration is non-cash, provide details<br> and an estimated valuation | N/A |
| Interest after change | N/A |
| + See chapter 19 for defined terms. | |
| --- | --- |
| Appendix 3Y Page 2 | 01/01/2011 |
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – Closed period
| Werethe interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
|---|---|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
| + See chapter 19 for defined terms. | |
|---|---|
| 01/01/2011 | Appendix 3Y Page 3 |
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced30/9/2001. Amended 01/01/11
| Nameof Entity: | Radiopharm<br>Theranostics Limited (ASX: RAD) |
|---|---|
| ABN: | 57<br>647 877 889 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of<br>Director: | Paul Hopper |
|---|---|
| Date of Last Notice: | 10 December 2024 |
Part 1 - Changeof director’s relevant interests in securities
In the case of a trust, thisincludes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or Indirect Interest | Direct | ||
|---|---|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | |||
| Date of change | 16 December 2024 | ||
| No. of securities held prior to change | Shares | Options | |
| --- | --- | --- | --- |
| Direct | 53,900,000 | 27,500,000 | |
| Indirect | 93,821,428 | 9,017,518 | |
| Total | 147,721,428 | 36,517,518 | |
| Class | Unlisted options | ||
| --- | --- | ||
| Number acquired | Shares | Options | |
| --- | --- | --- | --- |
| Direct | - | 8,000,000 | |
| Indirect | - | - | |
| **** | Total | - | 8,000,000 |
| + See chapter 19 for defined terms. | |||
| --- | --- | ||
| 01/01/2011 | Appendix 3Y Page 1 |
Appendix 3Y
Change of Director’s Interest Notice
| Number disposed | Shares | Options | |
|---|---|---|---|
| Direct | - | - | |
| Indirect | - | - | |
| Total | - | - | |
| Value/Consideration<br><br> <br>Note:<br><br> <br>If consideration<br> is non-cash, provide details and estimated valuation | Non-cash options issued, per resolution 6 approved by shareholders<br>at the Annual General Meeting held on 25 November 2024 | ||
| --- | --- | ||
| No. of securities held after change | Shares | Options | |
| --- | --- | --- | --- |
| Direct | 53,900,000 | 35,500,000 | |
| Indirect | 93,821,428 | 9,017,518 | |
| **** | Total | 147,721,428 | 44,517,518 |
| Nature of change<br><br> <br>Example:<br><br> <br>on-market trade,<br> off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Per resolution 6 approved by shareholders at the Annual General Meeting<br>held on 25 November 2024 | ||
| --- | --- |
Part 2 –Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A |
|---|---|
| Nature of interest | N/A |
| Name of registered holder<br><br> <br>(if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change<br><br> <br>Note: Details<br> are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration<br><br> <br>Note: If consideration is non-cash, provide details<br> and an estimated valuation | N/A |
| Interest after change | N/A |
| + See chapter 19 for defined terms. | |
| --- | --- |
| Appendix 3Y Page 2 | 01/01/2011 |
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – Closed period
| Werethe interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
|---|---|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
| + See chapter 19 for defined terms. | |
|---|---|
| 01/01/2011 | Appendix 3Y Page 3 |
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced30/9/2001. Amended 01/01/11
| Nameof Entity: | Radiopharm<br>Theranostics Limited (ASX: RAD) |
|---|---|
| ABN: | 57<br>647 877 889 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of<br>Director: | Riccardo Canevari |
|---|---|
| Date of Last Notice: | 18 September 2024 |
Part 1 - Changeof director’s relevant interests in securities
In the case of a trust, thisincludes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or Indirect Interest | Direct | ||
|---|---|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | |||
| Date of change | 12 December 2024 – 16 December 2024 | ||
| No. of securities held prior to change | Shares | Options | |
| --- | --- | --- | --- |
| Direct | 12,253,584 | 55,699,013 | |
| Indirect | 1,150,000 | - | |
| Total | 13,403,584 | 55,699,013 | |
| Class | RAD Ordinary Fully<br>Paid Shares<br><br><br><br>Unlisted Options | ||
| --- | --- | ||
| Number acquired | Shares | Options | |
| --- | --- | --- | --- |
| Direct | 7,776,402 | 55,250,286 | |
| Indirect | - | - | |
| **** | Total | 7,776,402 | 55,250,286 |
| + See chapter 19 for defined terms. | |||
| --- | --- | ||
| 01/01/2011 | Appendix 3Y Page 1 |
Appendix 3Y
Change of Director’s Interest Notice
| Number disposed | Shares | Options | |
|---|---|---|---|
| Direct | - | ||
| Indirect | - | - | |
| Total | - | ||
| Value/Consideration<br><br> <br>Note:<br><br> <br>If consideration<br> is non-cash, provide details and estimated valuation | 1) <br> 684,787 shares purchased at $0.028 and $0.029 per share.<br><br> <br><br><br> <br>2) <br> $0.031 per share.<br><br> <br><br><br> <br>3) Non-cash options issued, per resolution 7 approved by shareholders<br> at the Annual General Meeting held on 25 November 2024 | ||
| --- | --- | ||
| No. of securities held after change | Shares | Options | |
| --- | --- | --- | --- |
| Direct | 20,029,986 | 110,949,299 | |
| Indirect | 1,150,000 | - | |
| **** | Total | 21,179,986 | 110,949,299 |
| Nature of change<br><br> <br>Example:<br><br> <br>on-market trade,<br> off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | 1) On-market trades<br><br> <br><br><br> <br>2) Issuance of shares per pre-employment contract.<br><br> <br><br><br> <br>3) Issuance of options per resolution 7 approved by shareholders<br> at the Annual General Meeting held on 25 November 2024. | ||
| --- | --- |
Part 2 –Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A |
|---|---|
| Nature of interest | N/A |
| Name of registered holder<br><br> <br>(if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change<br><br> <br>Note: Details<br> are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration<br><br> <br>Note: If consideration is non-cash, provide details<br> and an estimated valuation | N/A |
| Interest after change | N/A |
| + See chapter 19 for defined terms. | |
| --- | --- |
| Appendix 3Y Page 2 | 01/01/2011 |
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – Closed period
| Werethe interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
|---|---|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
| + See chapter 19 for defined terms. | |
|---|---|
| 01/01/2011 | Appendix 3Y Page 3 |
Exhibit 99.4
| Appendix<br> 3H - Notification of cessation of securities |
|---|
Announcement Summary
Entityname
RADIOPHARM THERANOSTICS LIMITED
AnnouncementType
New announcement
Dateof this announcement
Wednesday December 18, 2024
Detailsof +securities that have ceased
| ASX +security | Date of | ||||
| code | Security<br> description | The<br> +securities have ceased due to | cessation | ||
| RADAK | OPTION<br>EXPIRING 01-JUN-2027 EX 0.60 | 833,500 | Lapse of<br> conditional right to securities because the<br> conditions have not been, or have become incapable of being,<br> satisfied | 16/12/2024 | |
| RADAN | OPTION EXPIRING<br> VARIOUS DATES EX VARIOUS PRICES | 3,517,676 | Lapse of conditional right<br> to securities because the conditions<br> have not been, or have become incapable of being,<br> satisfied | 16/12/2024 |
All values are in US Dollars.
Refer to next page for full details of the announcement
| Appendix 3H - Notification of cessation of securities | 1 / 4 |
| --- | --- | | Appendix<br> 3H - Notification of cessation of securities | | --- |
Part 1 - Announcement Details
1.1Name of +Entity
RADIOPHARM THERANOSTICS LIMITED
We (the entity named above) provide the following information about our issued capital.
| 1.2 Registered Number Type | Registration Number |
|---|---|
| ACN | 647877889 |
| 1.3 ASX issuer code | |
| --- | |
| RAD | |
| 1.4 The announcement is | |
| New announcement | |
| 1.5 Date of this announcement | |
| 18/12/2024 |
| Appendix 3H - Notification of cessation of securities | 2 / 4 |
| --- | --- | | Appendix<br> 3H - Notification of cessation of securities | | --- |
Part 2 - Details of +equity securities or +debt securities that have ceased
ASX+Security Code and Description
RADAK : OPTION EXPIRING 01-JUN-2027 EX $0.60
Unquoted+equity securities that have ceased
Numberof securities that have ceased
833,500
Reasonfor cessation
Lapse of conditional right to securities because the conditions have not been, or have become incapable of being, satisfied
| Date of cessation | Is the entity paying any consideration for the cessation? |
|---|---|
| 16/12/2024 | No |
Anyother information the entity wishes to notify to ASX about the cessation?
ASX+Security Code and Description
RADAN : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES
Unquoted+equity securities that have ceased
Numberof securities that have ceased
3,517,676
Reasonfor cessation
Lapse of conditional right to securities because the conditions have not been, or have become incapable of being, satisfied
| Date of cessation | Is the entity paying any consideration for the cessation? |
|---|---|
| 16/12/2024 | No |
Anyother information the entity wishes to notify to ASX about the cessation?
| Appendix 3H - Notification of cessation of securities | 3 / 4 |
| --- | --- | | Appendix<br> 3H - Notification of cessation of securities | | --- |
Part 3 - Issued capital following changes
Followingthe cessation of the +securities the subject of this notification, the issued capital of the entity will comprise:
The figures in parts 3.1 and 3.2 below are automatically generated and may not reflect the entity’s current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.
3.1Quoted +equity securities and +debt securities (total number of each +class of +securities quoted on ASX)
| ASX +security code and description | Total number of +securities on issue | |
|---|---|---|
| RADO : OPTION EXPIRING 30-NOV-2026 | 79,352,040 | |
| RAD : ORDINARY FULLY PAID | 2,172,960,756 | |
| RADOA : OPTION EXPIRING 24-AUG-2026 | 818,890,534 |
3.2Unquoted +equity securities (total number of each +class of +equity securities issued but not quoted on ASX)
| ASX +security code and description | |
|---|---|
| RADAK : OPTION EXPIRING 01-JUN-2027<br> EX 0.60 | 1,666,500 |
| RADAE : OPTION EXPIRING 25-NOV-2025 RESTRICTED | 5,700,006 |
| RADAN : OPTION EXPIRING VARIOUS DATES EX VARIOUS<br> PRICES | 68,744,711 |
| RADAJ : OPTION EXPIRING 01-JUL-2027 EX 0.17 | 13,137,976 |
| RADAF : OPTION EXPIRING 25-NOV-2026 RESTRICTED | 8,666,678 |
| RADAG : OPTION EXPIRING 25-NOV-2026 EX 0.60 | 5,066,672 |
| RADAH : OPTION EXPIRING 22-DEC-2025 EX 0.60 | 400,000 |
| RADAI : OPTION EXPIRING 27-MAY-2027 EX 0.60 | 740,000 |
| RADAP : OPTION EXPIRING 24-APR-2028 EX 0.09 | 8,955,224 |
| RADAAA : OPTION EXPIRING 24-FEB-2025 EX 0.05 | 149,925,040 |
All values are in US Dollars.
Note: the figures stated in the tables above are used to calculate the total market capitalisation of the entity published by ASX from time to time. The table will not include those classes of +securities that have ceased or lapsed in their entirety in ASX records before the announcement date described in Q1.5, even if the entity has advised ASX of a change to that class of +security in Part 2 of this form.
| Appendix 3H - Notification of cessation of securities | 4 / 4 |
| --- | --- |